

UCSF

UC San Francisco Previously Published Works

Title

Study Protocol for “Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study”

Permalink

<https://escholarship.org/uc/item/39h8c032>

Authors

Spriggs, Meg J
Douglass, Hannah M
Park, Rebecca J
et al.

Publication Date

2021

DOI

10.3389/fpsy.2021.735523

Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed



Study Protocol for “Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study”

Meg J. Spriggs^{1*}, Hannah M. Douglass¹, Rebecca J. Park², Tim Read¹, Jennifer L. Danby¹, Frederico J. C. de Magalhães¹, Kirsty L. Alderton¹, Tim M. Williams¹, Allan Blemings¹, Adele Lafrance³, Dasha E. Nicholls⁴, David Erritzoe¹, David J. Nutt¹ and Robin L. Carhart-Harris¹

OPEN ACCESS

Edited by:

Antonio Metastasio,
Camden and Islington NHS
Foundation Trust, United Kingdom

Reviewed by:

Daryl Wayne Niedermoser,
University Psychiatric Clinic
Basel, Switzerland
Allan Kaplan,
Centre for Addiction and Mental
Health (CAMH), Canada

*Correspondence:

Meg J. Spriggs
m.spriggs@imperial.ac.uk

Specialty section:

This article was submitted to
Psychological Therapies,
a section of the journal
Frontiers in Psychiatry

Received: 02 July 2021

Accepted: 15 September 2021

Published: 20 October 2021

Citation:

Spriggs MJ, Douglass HM, Park RJ, Read T, Danby JL, de Magalhães FJC, Alderton KL, Williams TM, Blemings A, Lafrance A, Nicholls DE, Erritzoe D, Nutt DJ and Carhart-Harris RL (2021) Study Protocol for “Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study”. *Front. Psychiatry* 12:735523. doi: 10.3389/fpsy.2021.735523

¹ Centre for Psychedelic Research, Department of Brain Sciences, Imperial College London, London, United Kingdom,

² OxBR EaD Research Group, Department of Psychiatry, University of Oxford, Oxford, United Kingdom, ³ School of Rural and Northern Health, Laurentian University, Sudbury, ON, Canada, ⁴ Division of Psychiatry, Department of Brain Sciences, Imperial College London, London, United Kingdom

Background: Anorexia nervosa (AN) is a serious and life-threatening psychiatric condition. With a paucity of approved treatments, there is a desperate need for novel treatment avenues to be explored. Here, we present (1) an overview of the ways through which Public Patient Involvement (PPI) has informed a trial of psilocybin-assisted therapy for AN and (2) a protocol for a pilot study of psilocybin-assisted therapy in AN currently underway at Imperial College London. The study aims to assess the feasibility, brain mechanisms and preliminary outcomes of treating anorexia nervosa with psilocybin.

Methods: (1) PPI: Across two online focus groups, eleven individuals with lived experience of AN were presented with an overview of the protocol. Their feedback not only identified solutions to possible barriers for future participants, but also helped the research team to better understand the concept of “recovery” from the perspective of those with lived experience. (2) Protocol: Twenty female participants [21–65 years old, body mass index (BMI) 15 kg/m² or above] will receive three oral doses of psilocybin (up to 25 mg) over a 6-week period delivered in a therapeutic environment and enveloped by psychological preparation and integration. We will work with participant support networks (care teams and an identified support person) throughout and there will be an extended remote follow-up period of 12 months. Our two-fold primary outcomes are (1) psychopathology (Eating Disorder Examination) across the 6-month follow-up and (2) readiness and motivation to engage in recovery (Readiness and Motivation Questionnaire) across the 6-week trial period. Neurophysiological outcome measures will be: (1) functional magnetic resonance imaging (fMRI) brain changes from baseline to 6-week endpoint and (2) post-acute changes in electroencephalography (EEG) activity, including an electrophysiological marker of neuronal plasticity.

Discussion: The results of this pilot study will not only shed light on the acceptability, brain mechanisms, and impression of the potential efficacy of psilocybin as an adjunct treatment for AN but will be essential in shaping a subsequent Randomised Control Trial (RCT) that would test this treatment against a suitable control condition.

Clinical Trial Registration: identifier: NCT04505189.

Keywords: psilocybin, anorexia nervosa, clinical trial, eating disorder, magnetic resonance imaging (MRI), electroencephalograph (EEG), public patient involvement (PPI), psychedelic-assisted therapy

INTRODUCTION

“In the core you are always yourself, but during an eating disorder you lose yourself... looking back I was just a hollow kind of body... you lose yourself in the process but you find yourself again and you also create new... I reinvented myself but then I also reconnected with what I always was.” (Focus group 2, A1).

Anorexia nervosa (AN) is a serious psychiatric condition. The Diagnostic and Statistical Manual of Mental Disorders (DSM-5) (1) defines AN by severe nutritional restriction, an intense fear of gaining weight, and a disturbance of one’s bodily self-perception. Prevalence rates are highest in females (approximate lifetime prevalence of 1.2–2.2%), and onset is most common in adolescence or early adulthood (2, 3). AN is not a Western-bound illness, nor is it constrained to those of a particular age, gender, culture or ethnicity (4–7).

AN is the most fatal of all psychiatric conditions. Mortality rates are 11.6 times higher than the general population (8). Of these premature deaths, 25% result from suicide, with the reported suicide rate in AN up to 56 times that of the global average (9). Treatment dropout rates in adult patients are also staggeringly high with 20 to 50% of inpatients, and up to 70% of outpatients ending treatment prematurely (3, 10–12). Fewer than half of those diagnosed reach remission after specialist treatment (13, 14) and for 20–30%, AN is a life-long condition (15, 16)¹. Despite these high mortality and low remission rates, AN research remains severely underfunded with <1% of (the already limited) mental health research funding in the UK allocated to eating disorders, compared with up to 9% for depression (13, 18, 19).

In recent years there has been a surge of interest in the therapeutic use of classic psychedelic drugs; a class of drugs including lysergic acid diethylamide (LSD), psilocybin (the principal psychedelic molecule in magic mushrooms), and dimethyltryptamine (DMT, the principal psychedelic molecule in ayahuasca). There is a growing list of clinical trials highlighting the potential efficacy of psychedelic therapy across conditions (20) including various addictions (21–23), obsessive-compulsive disorder (24), depression (25–29), and end-of-life anxiety (30–33).

¹There is debate over the most appropriate treatment target and avenue for Severe Enduring Anorexia Nervosa (SEAN); for example, whether quality of life is a more appropriate target than weight restoration, whether compulsory treatment should be repeatedly enforced, or whether, in some cases, palliative care is instead justified (16, 17).

The primary receptor-level mechanism of action of classic psychedelics is thought to be via agonism of the serotonin 2A (5-HT_{2A}) receptor. This is understood to induce a spike to wave decoherence that leads to an associated acute “entropic brain state” whereby the spontaneous activity of neural ensembles becomes dysregulated. This 5-HT_{2A} stimulation also induces a hyper-plastic state and a speculated relaxation of the precision weighting of implicit predictive mechanisms. Within the right context, this is thought to promote rapid and deep learning and open a window of opportunity for meaningful psychological transformation (34–37). There is also now an increasing understanding that it is the *quality* rather than the *intensity* of the acute experience that is predictive of long-term therapeutic outcomes (21, 31, 33, 38–40) with growing recognition for the importance of acute emotional-breakthroughs (41, 42).

In AN, aberrant serotonergic activity (43) and reduced synaptic plasticity-related brain-derived neurotrophic factor (BDNF) serum concentrations (44) are thought to contribute to the psychopathology. AN is also characterised by cognitive rigidity (45, 46) and experiential (47) or emotional avoidance (48, 49). Such traits have been demonstrated to change following a meaningful psychedelic experience where the experience of intense emotional states is an important part of the therapeutic process (25, 41, 50, 51). Based on both this neurobiological and psychological evidence, psilocybin assisted-therapy deserves consideration as a potentially novel therapeutic avenue for AN.

There is also preliminary evidence for the efficacy of psychedelics in the treatment of AN. A single case study from 1959 presents a female patient (Miss Henriette B...) for whom two doses of intravenous psilocybin induced “indisputable” therapeutic action (52). Most notable were the patient’s acute insights into the perceived root causes of her symptoms, post-acute improvements in mood and well-being, and subsequent weight restoration. Following participation in ceremonial ayahuasca experiences, Lafrance and colleagues reported a reduction or cessation of ED symptoms, improvement in body perception, and increases in self-acceptance in qualitative reports from those with a diagnosis of an ED (53, 54). Finally, in a prospective study, Spriggs et al. (42) demonstrated reductions in depressive symptoms and increases in well-being 2 weeks after a self-initiated psychedelic experience in those reporting a lifetime diagnosis of an ED, with supportive evidence for a role for acute emotional breakthroughs in mediating this change.

These strands of evidence support an early phase clinical trial into the potential of psilocybin-assisted therapy to treat AN. We are not alone in this surmise (55). At the point

of writing, there are three trials of therapy with psilocybin (NCT04052568, NCT04505189, NCT04661514) and one study of therapy with 3,4-Methylenedioxy methamphetamine (MDMA; NCT04454684) either currently underway or planned in this population. In summary this represents a novel application for the burgeoning field of psychedelic-assisted therapy, as well as a potential opportunity to address the dire need for new treatment options for AN. Here, we present the protocol for a trial of psilocybin as a treatment for AN that is taking place at the Centre for Psychedelic Research, Imperial College London. First however, we demonstrate how Public Patient Involvement (PPI) was incorporated into the development of the trial, and how this has been crucial in shaping how it will be conducted.

PUBLIC PATIENT INVOLVEMENT

PPI is research carried out *with* or *by* members of the public rather than *to* or *about* them (56, 57). There is growing recognition for the important role for PPI in producing relevant, transparent and accountable research (57, 58). While there is no indication that PPI has been widely utilised in psychedelic research to date, two other publications in this special issue of *Frontiers Psychiatry* emphasise the importance of PPI to this field [Bornemann (under review)², (59)].

In preparation for this study, we conducted two online PPI focus groups (60). The aims of the focus groups were to (1) identify common concerns among individuals with AN regarding our trial design, (2) explore common barriers that individuals with AN face when engaging in treatment/research, (3) identify practical ways of addressing relevant barriers. Here we report the methods, outcomes and reflections from our PPI focus groups in accordance with the GRIPP2 reporting checklist (61).

PPI Methods

Attendees were invited to take part through poster advertisements on social media. Two 2-hour focus groups were held online with different groups of attendees. The focus groups were facilitated by three members of the trial's research team: a lead facilitator (MS), a scribe (HD), and a psychiatrist for mental health support (KA or FM). Eleven females aged 19 to 35 ($M = 25.36$, $SD = 4.80$) in various stages of treatment/recovery from AN attended one of the two focus groups. Attendees were reimbursed for their time.

Each focus group started with a brief presentation outlining the study design. Attendees were then invited to ask questions and provide feedback. An open discussion was then facilitated which was loosely centred on one or both of two broad questions: (1) what blocks have you faced in treatment for anorexia? (Focus group 1) and (2) what does "recovery" mean to you? (Focus group 1 & 2). Following the focus group, attendees were also invited to speak to the lead facilitator one-to-one. In the focus groups, attendees were encouraged to develop ideas collaboratively, while the one-to-one calls gave each attendee a further opportunity to share more personal or sensitive reflections.

Following each focus group, key themes from the discussions were identified by the lead facilitator and a summary document was created that outlined these themes and the implications for the trial. All attendees were invited to provide feedback on the summary document from their group, as well as feedback on the session itself. Specific consent was obtained to use quotes included in these summary documents for future publications and public engagement.

Brent National Research Ethics Service (NRES) and the Imperial College Research Governance and Integrity Team (RGIT) were consulted about all proposed activities. As this investigation was classified as PPI, no specific ethical approval was required for this component of the project.

PPI Results and Discussion

Barriers to Engagement

The most pertinent barrier to engaging in treatment identified by attendees was a focus on weight restoration. While authoritarian refeeding regimes can be a lifesaving necessity in AN treatment, it is felt that they overlook the importance of the psychological factors underlying these issues (62–64) which leaves patients feeling powerless, alienated from their bodies, and misunderstood (12, 65, 66). One focus group attendee reflected that previous treatments had left her feeling "*backed into a corner, I felt like an animal backed into a cage*" (Focus group 1, A5) while another described a disconnect that "*When the therapist is overly focused on a goal recovery weight, that doesn't correlate with feeling better!*" (Focus group 1, A1). Focus group attendees were reassured to know that, while we acknowledge that there is no definition of recovery from AN that does not include weight restoration (and negotiating this tension is a key part of the therapeutic process), our outcome measures do not focus on weight, but rather on the eating disorder psychopathology central to their distress. It was agreed that anxiety around weight checks will be minimised by ensuring that participants are aware of weight checks ahead of time, and that this information is being recorded primarily for safety and monitoring purposes as opposed to as an expected outcome.

Focus group attendees also identified a "reluctance to give up control" as being one of the key barriers that they would face in participating in a trial such as this. The idea of taking a drug that would induce a psychedelic experience felt particularly intimidating:

"I've done so many bad things and whatever, but touching drugs, definitely would be scary..." (waving hands for no; Focus group 1, A1).

In AN treatments, moving through significant "negative" emotions mid-treatment has been associated with improved outcomes (67). Psychedelic experiences can also be experienced as more challenging in the short term as one struggles to grapple with new insights (68). Focus group attendees were aware of the potential for this:

"What do I do with the deluge that comes when the dam is broken?" (Focus group 1, A2).

²Bornemann J, Close JB, Spriggs MJ, Carhart-Harris RL, Roseman L. *Psychedelic Self-Medication for Chronic Pain: A Qualitative Investigation* (under review).

Importantly, attendees also suggested a number of steps to overcome this “giving up control” barrier. Firstly, providing adequate information on the safety and acute effects of psilocybin may help participants to feel more at ease. Secondly, building a trusting relationship between the participant and the guides was identified as pivotal. As stated by one attendee:

“They know if they want to open their eyes that you will be sitting next to them with a hand to hold. Sometimes that is more important than information on how it works.” (Focus group 2, A5).

Third, advanced practical planning around dosing days (e.g., meal planning, weight checking and accommodation) will increase trust and enable greater engagement with the therapy. We have added this as one of the focuses of participants’ first preparation calls with their guide team (see section Psilocybin-Assisted Therapy for further information). Finally, attendees suggested that establishing good communication with support networks would help participants to feel that they have a plan for when the trial is over, which may create space for greater engagement. This is also consistent with our conjecture that support network involvement will be important for bridging the insights gained during the trial into real world behaviour changes, which has been incorporated into our trial procedures (see section Support Person Involvement for further information).

What Is “Recovery” From AN?

When posed with the question “what does “recovery” mean to you?,” both groups not only emphasised the importance of looking beyond diagnostic criteria, but also demonstrated the extent to which the definition of recovery varies from person to person and throughout the different phases of the recovery process. One consistent element however, was that both focus groups identified *rediscovery of identity* as a key component of recovery. AN is commonly regarded as an “egosyntonic” condition, where the disorder is central to one’s identity and value system (64, 69–72). The existential threat of recovery as a process of generating a new self-identity (64, 71–73) was reflected in both focus groups:

“So, I sort of get quite scared of the idea of trying to like, find those boundaries between me and the illness and wondering who I would be without it when I have lived my entire life building my sense of self while also having this there... what is life without it? That is my big black hole that puts me off going further in any kind of recovery or, like, actively engaging in recovery.” (Focus group 1, A2).

“You get so interwoven with the illness...it can be hard to separate the two out so in some ways it is easier to just rebuild yourself... until someone says to you, like, “who do you want to be? What identity do you want to have now? you can do whatever you want essentially,” there is no hope.” (Focus group 2, A4).

Contrary to popular belief, physical appearance did not emerge as being at the core of what those with AN value about their condition. Instead, focus group attendees appeared cognisant of other functional roles their AN served and how difficult it would be to let them go:

“You have no control over the things that are going on externally that are making you go crazy or hurting you or causing you pain, but oh yea damn you can really, you can control how much you love yourself and your nutritional intake in a heartbeat.” (Focus group 2, A5).

“... You’ve been holding on to it for so long, it was kind of that thing that keeps your head above the water so you wouldn’t drown, and so letting go of that it really feels as if I am going to drown if I let go of that because I don’t know who I am anymore.” (Focus group 1, A4).

This is consistent with previous research in which those with AN report that AN offers a sense of security/control over emotions, a communication tool, and a form of mastery over their body and life (66, 69, 74–76). From this perspective, AN represents a predominant identification with the body-object (i.e., the *lived body for others*) over the body-subject (i.e., the *body experienced from within*) (76–78), where the body represents a “concretised metaphor” for an inner experience (76).

With this in mind, it is evident that a disconnect in the definition of recovery between patients with AN and clinicians could contribute to one of the most widely recognised features of AN: high ambivalence toward recovery and an intense fear of engaging in the recovery process³. In other words, those with AN feel trapped between logic and emotion; while they know they must eat to survive, they cannot help but feel fearful of it. This creates a state of ambivalence and a low motivation to engage in treatment that evokes anxiogenic states (73). Focus group attendees reflected on times when they had felt *willing* to recover, but *unable, unmotivated, or not ready*.

“I wanted to recover, but I also didn’t have the motivation, and I wasn’t ready” (Focus group 2, A1).

“There was a willingness to get better, but I just couldn’t” (Focus group 2, A2)

Across previous studies, both clinicians and patients agree that increasing willingness and motivation to recover is an essential first step of any effective treatment (64, 70, 81). We therefore see this as an important outcome for this trial.

“I think that for a lot of people, they chase this concept of recovery when it doesn’t, for some people, you know there is no definition of what it means so it’s kind of impossible to chase... integrating it and making peace with the fact that you have this and taking anxiety away from having those thoughts and just accepting it is something that I can see as being a good outcome of this kind of therapy.” (Focus group 2, A4).

PPI Reflections

Each group was comprised of attendees with differing experience and knowledge of psychedelics and for some attendees, this

³While some have argued that AN is characterised by a lack of insight into the seriousness of the condition (69, 79, 80), it may be that, at least in some cases, this is rather a projection of the internal contradiction between simultaneously held beliefs (i.e., a projection of ambivalence) than a lack of insight *per se*.

TABLE 1 | Key inclusion and exclusion criteria for the trial.**Inclusion criteria**

Primary diagnosis of AN for more than 3 years
 Current or past treatments have not been successful to maintain remission
 21–65 years of age
 Female at birth^a
 In the care of a UK GP and specialist ED team, and agree to have us maintain contact with both for the duration of the trial
 Sufficient competency with the English language
 BMI \geq 15 kg/m² and medically stable
 Capacity to consent
 Agreement to have us maintain contact with an identified support person

Exclusion criteria

Current or previously diagnosed psychotic disorder, significant history of mania, or evidence of a personality disorder
 Immediate family member with a diagnosed psychotic disorder
 Unstable physical condition. This includes rapid weight loss $>$ 2 kg in the prior month, abnormal serum electrolytes, raised cardiac enzymes, hepatic or renal dysfunction, abnormal QT interval prolongation (QTc above 470 ms)
 Medical condition unsuitable for psilocybin, EEG or MRI
 History or laxative abuse in the previous 3 months, or drug dependence in the previous 6 months
 History of serious suicide attempts or presence of a suicide/serious self-harm risk at screening
 Currently an inpatient
 Blood or needle phobia
 Positive pregnancy test or breastfeeding
 Sexually active and lacking appropriate contraceptive means
 No email access
 Enrolled in another clinical trial of an investigational medicinal product (CTIMP) in the last 3 months

^aWhile the exclusion of males may appear at odds with the inclusive approach we wish to embody, we also recognise that the presentation and treatment needs of males with AN differ from those of females (85, 86). AN is also significantly less common in males [estimates of male EDs range from approximately 10 to 25% of cases (7, 87)], rendering recruitment of a balanced sample difficult.

was the first time they had heard of psychedelic-assisted psychotherapy. Because of this, the conversations did not centre as much on the specifics of the psychedelic experience *per se*, rather on aspects relevant to carrying out such a trial with people with AN. Importantly, we were able to identify key barriers to participation and develop strategies to help manage these. Additionally, the focus groups helped us to recognise the importance of trial participants being supported to develop their own understanding of recovery as a way of promoting motivation to engage in treatment. A study measure has subsequently been developed to capture this (the self-constructed “Recovery Interview”).

The use of focus groups not only fostered collaboration but had an unexpected positive impact on attendees who reported feeling a sense of community and understanding in recovery. Giving those with lived experience an opportunity to be heard was a rewarding experience for researchers and attendees alike. One limitation of these focus groups was the lack of diversity in the groups themselves. In future, we will endeavour to advertise PPI more broadly and will seek to actively engage with seldom-heard groups. A further limitation is that focus group attendees

were largely ineligible for the study itself due to, for example, their age, location, stage of recovery, or current treatment. While a number of the attendees saw PPI as an alternative way of contributing to the study, some of the reflections shared may not be generalisable to study participants.

STUDY PROTOCOL: “PSILOCYBIN AS A TREATMENT FOR ANOREXIA NERVOSA: A PILOT STUDY”

Overview

Here we present the protocol for a pilot study that has been designed to assess the feasibility and preliminary outcomes of treating AN with psilocybin-assisted therapy. Additionally, the study aims to use Magnetic Resonance Imaging (MRI) and Electroencephalography (EEG) to examine the neuronal underpinnings of treatment with psilocybin in this group. Although pilot studies are often perceived as less impactful than larger scale RCTs, their potential influence in shaping the direction of future research should not be understated. It is the overarching goal of any pilot study to provide the optimal information needed to prepare for future studies, and they should therefore be held to the same level of methodological rigour as their larger-scale counterparts (82–84). A well-conducted pilot study will not only improve the resource efficiency of future large-scale studies but is also more ethical as it allows for a more data-driven approach to the development of key methods and outcomes (82). The outcomes of this study will sharpen the research focus and evaluate the utility and acceptability of study methods for implementation in a larger-scale (and therefore more costly) study.

Methods and Analysis

Recruitment and Selection

We will include twenty completing participants with a DSM-5 diagnosis of AN in this study, with “completion” defined as completing the entire final study visit. Key entry criteria can be found in **Table 1**. We have endeavoured to match our pilot study inclusion criteria to those that might be used for any future larger studies to best represent the target population⁴.

We will recruit via referrals from National Health Service (NHS) Trust specialist eating disorder teams, and through self-referrals from advertisements and word of mouth. Regardless of recruitment method, all participants will be required to be under the care of a specialist eating disorders service to participate, and we will contact their General Practitioners (GP) and eating disorder service to confirm eligibility.

GPs and eating disorder services will also be asked to confirm any medications their patient is currently taking. Patients with AN are often prescribed serotonergic medications such as selective serotonin reuptake inhibitor (SSRI) or atypical antipsychotics (e.g., quetiapine) to manage co-morbid depression or anxiety, but with limited efficacy in treating AN symptomology (88). As serotonergic medications attenuate the acute psychological effects of psychedelics (89) all such

⁴According to Thabane et al. (84), this is perhaps a more important consideration than sample size to ensure that outcomes are transferrable.

medication will need to be discontinued for the course of the study. The withdrawal of medication will occur in accordance with previous trials of psilocybin for depression from our Centre (25, 27) and within the guidelines set out by the Royal College of Psychiatrists (90).

Screening and Consent

The screening procedure will involve both telephone/video-call and in-person screening. Potential participants will be provided with a summary information document followed by a full participant information document prior to providing consent. Initial consent to take part in the screening process will occur during the first screening call. Full study consent will be obtained at the in-person screening visit. Due to the centrality of AN in self-identity and personal values, capacity to provide informed consent may be compromised when making treatment decisions (91). In line with Park and colleague's Oxford Neuroethics Framework for DBS in AN (91), capacity to consent will be assessed at screening using the MacArthur Competence Assessment Tool for Clinical Research (MacCAT-CR) (92, 93).

Potential participants will also be asked to identify a support person such as a family member or close friend, and this person will be contacted by the study team. Consent will be obtained from the support person to (1) provide support during the study (required for the potential participant's participation), and (2) take part in a support-person sub-study (optional). See the section Support Person Involvement for further information.

Study Visits

The timeline of the study visits can be found in **Figure 1** and an overview of all study measures and activities can be found in **Table 2**. Over a period of 6 weeks, participants who are deemed eligible at screening will partake in eight study visits, including three psilocybin dosing sessions of up to 25 mg. Across these eight visits, there will also be two MRI scans, five EEG recordings and a range of psychological measures (questionnaires and interviews). There will be a follow-up period of 12 months following the final study visit, with monthly data collection points for the first 6 months.

Baseline and 6-Week Follow-Up

Baseline and follow-up study measures will be collected both in person and remotely (via video-call and the online survey platform Alchemer). The baseline and 6-week follow-up visits (visit 2 and 9, respectively), will be run similarly and will include MRI and EEG. The MRI scanning procedure will take ~90 min, with the scan itself lasting 60 min. EEG recording will last ~40–60 min. The baseline day will also include a meeting with the guide team to prepare for the first dosing session the following day (more information below). The 6-week follow-up day will also include a final integration meeting with the guide team.

Psilocybin-Assisted Therapy

Each participant will be paired with two "guides" whom they will work with for the duration of the trial. In all cases, the guide pair will include a therapist and/or psychiatrist. Preparation will begin with two remote calls before an in-person session on the baseline day (visit 2). Preparation sessions for subsequent dosing days will primarily be conducted remotely, but can be conducted in-person




FIGURE 1 | Study timeline. Grey background represents the active trial period. Blue represents pre- and post-trial periods. Yellow, green and orange represent preparation, dosing and integration respectively. Time intervals between each study day (remote or visit) for the active period are included on the left of the figure.

if this is deemed appropriate and preferable by the participant and their guides.

Dosing days (visits 3, 5, and 7) will typically last ~8 h, with the acute effects of the drug lasting 4–6 h. A medical professional will be on site for the duration of the dosing sessions and will approve the participant for discharge at the end of the day. Participants will be encouraged to utilise optional overnight accommodation the night prior to and following dosing. Those who live near the study centre may choose to go home; in which case, a taxi will be provided.

In-person integration visits will occur the day after dosing (visits 4, 6, and 8). The integration itself is anticipated to last 1–3 h, and will be followed by an EEG. Remote integration calls will take place 1 week after dosing.

Consistent with previous studies of psilocybin-assisted therapy, dosing will take place in a therapeutic environment. Participants will be encouraged to lie in a semi-reclined position

and will be provided with an eye mask and headphones through which a specially designed music playlist is delivered.

The concomitant psycho-therapeutic models for psychedelic-assisted therapy have historically been informed by humanistic and psycho-analytic approaches, however, there has been growing interest in incorporating other evidence-based therapies into the psychedelic assisted model, such as Cognitive Behavioural Therapy [CBT (22, 124)] Acceptance and Commitment Therapy [ACT (125–127)], Motivational Interviewing (128), and Emotion-Focused Family Therapy [EFFT (129)]. There is also growing support for manualisation of adjunct therapeutic approaches (125, 126, 128). The manual for the current trial, which incorporates various approaches, will be made available upon completion. It is hoped that it will be useful in future trials and will continue to develop with the burgeoning field of psychedelic-assisted therapy.

Support Person Involvement

Given the complex and systemic nature of AN, it is highly recommended that the family and support networks be involved in the treatment process where appropriate (130). The involvement of key support people is also recognised to improve outcomes for all involved (131–134). Additionally, we recognise the important role that the support person will play in facilitating long-term change and the transition back into usual care once the 6-week trial is complete.

As part of the study, the participant's identified support-person will be actively involved in the study process. With prior consent from the support person (a necessary condition of participant's involvement in the trial), we will make contact with them prior to their respective participant starting the trial and 1 week after each dose to provide support, guidance and study-specific resources. Participants will be strongly encouraged to bring their support person with them to in-person visits to escort them between study activities. There will be scope for a participant's support person to enter the therapy room at the end of a session (preparation, dosing, integration), however they will not be present while the participant is still experiencing the acute drug effects, or at any point where this may impact the therapeutic intention of the trial, including study measures. Participants will always be consulted before inviting a support person to join a session.

We will also invite support people to take part in an optional Next-Of-Kin sub-study. This will consist of the completion of a questionnaire at baseline and at the 6-week endpoint, as well as a semi-structured interview at the end of the active 6-week trial period. Both the self-constructed questionnaire and interview have been designed to explore the support person's perspective on their loved one's eating disorder, their relationship with their loved one, and how this may have changed over the course of the trial.

General Analysis Strategy

Efficacy Outcomes

As there are no prior data on psychedelic-assisted therapy in AN and given that it is well-known that AN psychopathology can take time to shift, it seems important to focus on both short-term response to treatment (i.e., over the course of the 6-week trial),

and long-term changes in psychopathology (i.e., over the follow-up period). It is not uncommon for pilot studies to define more than one primary outcome, especially when one such measure is clinical and the other is not, and the goal of the study is to assess response to treatment effects and variance (83, 84). There will be no correction for multiple comparisons as this is an exploratory study and no confirmatory claims will be made. We will report significance testing but note that effect sizes, confidence intervals and trends will be more meaningful overall in determining the trajectory of future studies.

For all psychological outcomes, treatment effects will be established by comparing baseline measures with the 6-week endpoint and/or monthly for a follow-up period of 6 months and at 12 months. Where relevant, further analyses will be conducted between dosing sessions. These analyses will largely consist of frequentist analyses such as analysis of covariance (ANCOVA) by timepoint controlling for baseline measures where relevant, or linear mixed models.

Predictors of treatment response and measures of the acute experience will be incorporated in mediation/moderation analyses (e.g., path analysis or structural equation modelling). Where parametric assumptions do not hold, non-parametric alternatives will be employed. Bayesian approaches will also be flexibly used to supplement frequentist hypothesis testing and to explore the relative evidence for a given effect.

Feasibility Outcomes

Consistent with our feasibility goals, we will also report recruitment and retention rate⁵. A consort diagram will be presented displaying participant retention at each phase of the recruitment, screening and data collection process. We will report the numbers of individuals provided with participant information sheets who subsequently decided not to participate in the trial, number that underwent telephone screening and number of drop-outs. For full transparency on inclusivity, information on the demographics and reason for exclusion will be reported from the screening dataset.

The level and pattern of the missing data in baseline variables and outcome measures will be reported. Where relevant, the potential causes for missing data will be investigated and reported.

Reported Adverse Events (AEs) will be recorded for the duration of the study. AEs will be classified by the clinical team based on severity (mild = no interference with daily activities; moderate = some interference with daily activities; severe = prevents daily activities), whether they are expected or unexpected, and causality (related, possibly related, or unrelated to the IMP). AE summary tables will display the total number of participants reporting an AE, the percentage of participants (%) with an AE, and the number of events (E) reported. Serious AEs (SAEs) and Serious Adverse Reactions (SARs) are defined as any untoward medical occurrence or

⁵It has been suggested that the large number of measures in our study may lead to increases in drop-out rates. However, across previous trials of similar design in participants with depression and healthy volunteers, we did not have any drop-out for this reason. Drop-out rates will nevertheless be an important feasibility measure prior to a large-scale RCT.

TABLE 2 | Schedule of study activities.

Measures	Screening	6-Week study period					Monthly follow-up
		Baseline [#]	Prep days [*]	Dosing days	Integration days	6-Week endpoint [#]	
Enrolment							
Informed consent	x						
MacCAT-CR	x						
Physical examination (incl. bloods and ECG)	x						
Psychiatric assessment	x						
MINI	x						
Key study activities							
Psilocybin dosing				x			
MRI		x					x
EEG		x			x		x
Support person contact		-----					
GP and ED team contact		-----					
Eating habits monitoring		-----					
Mood monitoring		-----					
Physiological measures		-----					
Adverse events		-----					
Primary & key secondary outcomes							
RMQ	x	x	x			x	x
EDE (interview)		x				x	x^^
EDE-Q	x	x	x			x	x
Psychological outcome measures							
PHQ-9	x	x	x			x	x
BDI-II	x	x	x			x	x
WEMWBS		x	x			x	x
MPFI		x	x			x	x
b-EAQ		x			x	x	
Y-BCEDS		x				x	
CIA		x				x	x
RRS-ED		x				x	
STAI-T		x				x	
WCS		x	x			x	
SCS		x	x			x	x
EES		x	x			x	x
CFS		x	x			x	x
P-CAN		x	x			x	x
IDEA		x				x	x
MAIA		x				x	
Openness		x				x	
FSCS		x				x	
CEAS		x	x			x	
IUS		x				x	
Self-constructed items		x				x	
Support person questionnaire (self-constructed)		x				x	
Exploratory outcome measures		x	x			x	x
Acute & integration measures							
ASC				x			
CEQ				x			
MEQ				x			

(Continued)

TABLE 2 | Continued

Measures	Screening	6-Week study period					Monthly follow-up
		Baseline [#]	Prep days*	Dosing days	Integration days	6-Week endpoint [#]	
EBI				x			
PMQ				x			
SM-B				x			
Self-constructed acute measures				x			
Self-constructed integration measures					x	x	x
COE						x	x
Predictors							
ACE		x					
Credibility/expectancy		x					
SSS		x					
MODTAS		x				x	
STAR			x				
STAI-S				x			
PPS				x			
Self-constructed interviews							
Recovery interview		x				x	
(R)EB-Q			x	x		x	
Support-Person interview						x	
Final interview							x [^]
Behavioural measures							
TMT		x				x	x [^]
WCST		x				x	x [^]
LO-FPT		x	x			x	x ^{^^}
HRD		x				x	

[#]remote measures will be collected within 1 week of study visit.

*Prep day measures before dosing day 1 are included in the baseline survey.

[^]measures followed by ^{^^} are only included at 3 & 6 months. Measures followed by [^] are included only at 6 months.

MacCAT-CR, MacArthur Competence Assessment Tool for Clinical Research (92); MINI, Mini international neuropsychiatric interview (94); RMQ, readiness and motivation questionnaire (95); EDE, eating disorder examination (96); EDE-Q, eating disorder examination questionnaire (96); PHQ-9, patient health questionnaire-9 [(97), p. 9]; BDI-II, Beck Depression Inventory II (98); WEMWBS, Warwick-Edinburgh Mental Wellbeing Scale (99); MPFI, Multidimensional Psychological Flexibility Inventory (100); b-EAQ, brief experiential avoidance questionnaire (101); YBC-EDS, Yale-Brown Cornell Eating Disorder Scale (102); CIA, Clinical impairment inventory (103); RRS-ED, Ruminative response scale for eating disorders (48); STAI-T, state trait anxiety inventory trait subscale (104); WCS, Watts connectedness scale (self-constructed); SCS, self-compassion scale (105); EES, experience of embodiment scale (106); Cognitive Flexibility Scale (CFS) (107); P-CAN, Pros and Cons of Anorexia Scale; IDEA, Identity in Eating disorders scale (78); MAIA, Multidimensional Assessment of Interoceptive Awareness (108); FSCS, Function of self-criticism/attacking scale (109); CEAS, Compassionate Engagement and Action Scale—self compassion and compassion for others subscale (110); IUS, Intolerance to Uncertainty Scale (111); ASC, altered states of consciousness questionnaire (112); CEQ, challenging experiences questionnaire (113); MEQ, mystical experiences questionnaire (113); EBI, emotional breakthrough inventory (41); PMQ, Psychedelic Music Questionnaire; SM-B, State of Mindfulness- body subscale (114); COE, Centrality of Events Scale (115) ACE, adverse childhood events (116); SSS, short suggestibility scale (117); MODTAS, Modified Tellegen Absorption Questionnaire (118); STAR, scale to assess the therapeutic relationship (119); STAI-S, state trait anxiety inventory state subscale (104); PPS, psychedelic predictor scale (self-constructed); (R)EB-Q, relaxed embodied beliefs questionnaire (self-constructed); TMT, trail making test (120); WCST, Wisconsin card sorting task (121); LO-FPQ, Leeds Oxford food preference questionnaire (122); HRD, heartrate discrimination tasks (123).

effect that at any dose (i) results in death, (ii) is life-threatening, (iii) requires hospitalisation, or (iv) results in persistent or significant disability or incapacity. All SAEs and SARs will be reported to the PI, sponsors, and regulatory bodies within 24h of the study team being made aware of the event.

Study Measures

Primary Psychological Outcome Measures

The two primary outcome measures are the Eating Disorder Examination (EDE) and the Readiness and Motivation Questionnaire (RMQ) (Table 3).

The investigator-led EDE and its self-report counterpart, the Eating Disorder Examination Questionnaire (EDE-Q) are the most widely used indices of eating disorder psychopathology in research settings (96). Both measures assess the frequency and severity of eating disorder cognitions and behaviours over the past 28 days. The EDE interview, which is administered by a trained researcher, gives a detailed, objective assessment of psychopathology and is widely viewed as the “gold standard” measure. Because it provides a detailed measure of the range and severity of eating disorder features it is used in most treatment studies and in many other in-depth investigations of eating disorder psychopathology. The EDE will be administered four

TABLE 3 | Primary and key secondary outcomes.

Measure	Timepoints for analysis
Primary outcome	
Eating disorder examination (EDE) global (96)	Baseline–6-month follow-up Baseline–3-month follow-up Baseline–6-week follow-up
Readiness and motivation questionnaire (RMQ) pre-contemplation (95)	Baseline–6-week follow-up Comparison between dosing days
Key secondary outcomes	
Eating disorder examination questionnaire (EDE-Q) global (96)	Baseline–6-week follow-up Comparison between dosing days
RMQ pre-contemplation & EDE global	Change in RMQ from baseline–6 weeks as a predictor of change in EDE global across the 6-month follow-up

times throughout the study: baseline, 6-week endpoint, 3-month and 6-month follow-up. Change in EDE (global score) will act as primary/key secondary outcome for this study, which will be analysed (1) from baseline to 6-month follow-up, (2) from baseline to 3-month follow-up, and (3) from baseline to 6-week follow-up. Secondary analysis will be performed on the four subscales (restraint, eating concerns, shape concerns, weight concerns).

The EDE-Q is a self-report questionnaire based upon the EDE interview and may be used when it is impracticable or undesirable to employ the interview. Here, we use the EDE-Q as supplementary to the EDE as it is more practical for more regular and remote administration. The EDE-Q will be measured bi-weekly for the duration of the trial (with adjustments made to reference the relevant time-period), monthly for the first 6 months of the follow-up period, and once more at 12-months. A key secondary analysis will be performed on EDE-Q global scores between the dosing sessions. Secondary analysis will be performed on the four subscales (restraint, eating concerns, shape concerns, weight concerns).

Motivation for recovery is a widely acknowledged barrier to treatment for AN and an essential first step of any effective treatment (64, 70, 79, 81). The Readiness and Motivation Questionnaire (RMQ) provides total readiness scores (for pre-contemplation, action, internality, and confidence), as well as readiness scores for four domains of eating disorder psychopathology (cognition, restriction, bingeing, compensatory strategies) in reference to the past 2 weeks. Both the RMQ and the interview upon which it is based (the Readiness and Motivation Interview) have been demonstrated as reliable predictors of behaviour change (95, 135–138), with a decrease in pre-contemplation score most sensitive to change in AN (95, 138–140). The RMQ will be measured bi-weekly for the duration of the trial, monthly for the first 6 months of the follow-up period, and once more at 12-months. The primary comparison will be pre-contemplation scores between baseline and the end of the active trial period (6-week follow-up),

and between dosing days. Secondary analysis will also explore changes in other RMQ subscales, and additional time points.

Given the interplay between readiness for recovery and changes in eating disorder psychopathology, a final key secondary analysis will assess whether changes in RMQ during the trial period predict change in EDE/EDE-Q over the 6-month follow-up period.

Secondary Psychological Outcome Measures

Secondary psychological measures will explore other areas of psychopathology and impairment related to AN, including day-to-day impairment [Clinical Impairment Assessment (CIA) (103)], rumination [Ruminative-Response Scale for Eating Disorders (RRS-ED) (48)], and preoccupation and rituals [Yale-Brown Cornell Eating Disorder Scale (YBC-EDS) (102)]. Given evidence for the possible transdiagnostic efficacy of psilocybin (20), and high rates of comorbidity in AN (141), we will also measure changes in depression symptomology [Beck Depression Inventory 2 (BDI-II) (98), Patient Health Questionnaire (PHQ-9) (97)], and anxiety [State-Trait Anxiety Inventory- Trait (STAI-T) (104)].

As discussed in the PPI focus groups, recovery from AN does not only pertain to changes in clinical symptomology, but involves *rediscovery* and *reconnection* with one's self, and one's values. To measure changes in the broader impact of AN on participants' lives we have included measures of AN beliefs and values [Pros and Cons of Anorexia Scale (P-CAN) (75)], AN identity [Identity in Eating disorders scale (IDEA) (78)], embodiment [Experience of Embodiment Scale (EES) (106), Multidimensional Assessment of Interoceptive Awareness (MAIA) (108)], self-compassion [the Self-Compassion Scale (SCS) (105)], intolerance to uncertainty [Intolerance to Uncertainty Scale (IUS) (111)] and cognitive flexibility [Cognitive Flexibility Scale (CFS) (107)]. Based on previous psychedelic trials, we will also measure changes in more generalised constructs that have been shown to shift following psychedelic-assisted therapy and that have an important role in recovery from AN. This includes psychological well-being [Warwick-Edinburgh Mental Well-being Scale (WEMWBS) (99)], psychological flexibility (Multidimensional Psychological Flexibility Inventory (MPFI) (142), experiential avoidance [brief experiential avoidance questionnaire (BEAQ) (101)], and connectedness (Watt's Connectedness Scale).

Acknowledging that recovery from AN is a unique and personalised journey, and the exploratory nature of the trial, we have also included a variety of self-constructed qualitative/quantitative interviews. These measures explore topics such as individual definitions of recovery (the Recovery Interview), changes in embodied core beliefs [the (Relaxed) Embodied Beliefs Questionnaire ((R)EB-Q)], and experience of psilocybin therapy (6-month interview).

Finally, given the role of the acute experience in predicting psychological outcome following a psychedelic experience (40, 143), various measures of the acute experience have been included (Table 2). While there is a current lack of validated measures of integration, a mixture of validated and self-constructed measures of integration have also been included.

Neuroimaging

We will perform brain imaging (MRI) at baseline (visit 2), and 6-week follow-up (visit 9). Our primary imaging outcome measures will reflect functional (fMRI) brain changes and will include a change in task-based BOLD response and a change in resting-state activity and connectivity. As secondary measures, we will also assess structural changes (morphometry, cortical thickness and diffusion imaging).

Electroencephalography (EEG) will be collected at baseline (visit 2), integration 1 (visit 4), integration 2 (visit 6), integration 3 (visit 8), and 6-week follow-up (visit 9). Resting-state data will be collected at all time points. As a key index of induced changes in neuroplasticity, we will include the visual Long-Term Potentiation (LTP) paradigm (144) on integration days. The roving Mismatch Negativity (MMN) paradigm will also act to supplement neuroplasticity findings (145, 146).

Behavioural and Other Additional Measures

The Wisconsin Card Sorting Task [WCST, (121)] and Trail Making Test [TMT, (120)] will be conducted as measures of cognitive flexibility at baseline (visit 2), 6-week follow-up (visit 9) and during the 6-month follow-up. Interoceptive accuracy and precision will be assessed using the HeartRate Discrimination Task [HRD, (123)] at baseline (visit 2) and follow-up (visit 9). The Leeds-Oxford Food Preference Task [LO-FPT, (122)] will be employed to detect changes in preference for low-fat, high-fat, low-energy, and high-energy foods at baseline (visit 2), preparation days 2 and 3 (visits 4 and 6), follow-up (visit 9), and at the 3- and 6-month remote follow-ups. Physiological measurements (e.g., respiratory rate, heart rate variability, and accelerometry) may be collected from consenting participants throughout the study.

Data Management

Data will be managed as per the Imperial College Data Management Standard Operating Procedures and a study-specific data management plan (authored by MS). Data management will be overseen by the trial co-ordinator (MS).

The GDPR-compliant Psychedelic Survey platform (psychedelicsurvey.com) is an external software that was created for our centre and will be used to deliver remote survey measures. Participants will receive links to the surveys via email, to be completed on the separate survey hosting platform Alchemer, where we will store our data (to GDPR standards). In previous studies, this was found to be an efficient way to optimise collection and safe storage of questionnaire data, while also reducing human error, and so this procedure will be repeated for this trial. The WCST, TMT and LO-FPT will be hosted on the online behavioural task platform Cognitron, developed by the Imperial Computational, Cognitive, and Clinical Neuroimaging Laboratory. Participants will be delivered remote links to these tasks via the same Psychedelic Survey emails.

The study will be monitored internally by the Centre for Psychedelic Research, by Imperial College Healthcare NHS Trust, by Imperial College RGIT (sponsors) and it may also be audited by the MHRA. Any trial-related regulatory inspections will be

permitted and direct access to source data and documents will be provided.

Participant Safety and Monitoring

Participants' mood and eating habits will be monitored weekly from enrolment until the end of the 6-week active study phase using self-report measures administered via the remote survey platform. On weeks where no study visits are scheduled during the active study period, phone or video calls will allow the study team to check-in with the participant. Halfway through the trial, we will report back to the care team on any changes in the participants well-being or changes that are deemed clinically significant. Additionally, we will contact the participant's identified support person at set timepoints throughout the study. The study team will be contactable by the participant's care team and support person throughout the active study phase.

We will record participant's weight on five occasions throughout the study: screening (visit 1), baseline (visit 2), dosing day 2 (visit 5), dosing day 3 (visit 7), and 6-week follow-up (visit 9). This will be discussed with participants during the screening and preparation process to best manage any anxiety with weight checks. If rapid weight loss occurs (>2 kg in a month) participants will be withdrawn due to medical instability, and this will be reported to the relevant healthcare professional(s). Specific consent is obtained for weight information to be shared between the study team and the participants eating disorder team should this be required. Should there be any other significant deterioration in the participant's physical or mental health we will liaise with the relevant health professionals to determine whether it is safe, and in the participants best interests, to continue in the study. This will occur in discussion with the participant and the extended research team, if relevant.

IMP Management

A Schedule 1 licence has been obtained from the UK Home Office. Psilocybin has been supplied by Compass Pathways. Manufacture was performed by Onyx and encapsulation was performed by Catalent (formerly Juniper) pharmaceuticals. Bottling and labelling were performed by Fisher pharmaceuticals. Good Manufacturing Practise (GMP) has been maintained at all stages of manufacture. The IMP will be stored and dispensed by Invicro LLC.

Dissemination

The results of this study will be published in academic journals and presented in both the academic and public domain, including at scientific conferences and in the media in public engagement forums. Patient confidentiality will be maintained in all of the above.

Ethics Statement and Trial Registration

This is an investigator-initiated, university-sponsored trial. This trial has received a favourable opinion from Brent National Research Ethics Service (NRES) and is sponsored by Imperial College London's Research Governance and Integrity Team (RGIT, formerly the Joint Research Compliance Office; JRCO). It has been reviewed and approved by the Health Research Authority (HRA) and Medicines and Healthcare

products Regulatory Agency (MHRA). All staff have undergone Good Clinical Practise (GCP) training. The study has been adopted by the National Institute of Health Research (NIHR) Clinical Research Network (CRN) and has been registered on clinicaltrials.gov (NCT04505189). All study sessions will take place at the NIHR-funded Imperial College Research Facility (ICRF).

CONCLUSIONS

Here we have presented a trial protocol for an innovative pilot study assessing psilocybin-assisted therapy as a treatment component for AN. While this trial is one of many exploring psychedelics in mental health treatment, we wish to emphasise how incorporating the voices of those with lived experience has not been beneficial for adapting the psychedelic-therapy approach to this population, but has also been a rewarding experience for researchers and focus group attendees alike. We encourage the integration of PPI initiatives into future psychedelic research, and guidance for doing so has been presented by Close et al. (59).

It is hoped that by presenting our protocol in this format, we will improve the transparency and methodological rigour of the trial which, in turn, will enhance its impact. The insight gained from this pilot study will not only shed light on the potential of psilocybin-assisted therapy in the treatment of AN but will also provide a framework for a more efficient, ethical, and efficacious RCT in the future.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Brent National Research Ethics Service. The patients/participants will provide their written informed consent to participate in this study.

REFERENCES

1. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders (DSM-5®)*. Washington, DC: American Psychiatric Association (2013). doi: 10.1176/appi.books.9780890425596
2. Bulik CM, Sullivan PF, Tozzi F, Furberg H, Lichtenstein P, Pedersen NL. Prevalence, heritability, and prospective risk factors for anorexia nervosa. *Arch Gen Psychiatry*. (2006) 63:305–12. doi: 10.1001/archpsyc.63.3.305
3. Jagielska G, Kacperska I. Outcome, comorbidity and prognosis in anorexia nervosa. *Psychiatr Pol*. (2017) 51:205–18. doi: 10.12740/PP/64580
4. Aigner M, Treasure J, Kaye W, Kasper S, Disorders WFTOE. World federation of societies of biological psychiatry (WFSBP) guidelines for the pharmacological treatment of eating disorders. *World J Biol Psychiatry*. (2011) 12:400–43. doi: 10.3109/15622975.2011.602720
5. Hamilton JD. Eating disorders in preadolescent children. *Nurse Pract*. (2007) 32:44–8. doi: 10.1097/01.NPR.0000263088.93771.30
6. Mangweth-Matzek B, Rupp CI, Hausmann A, Assmayr K, Mariacher E, Kemmler G, et al. Never too old for eating disorders or body dissatisfaction: a community study of elderly women. *Int J Eat Disord*. (2006) 39:583–6. doi: 10.1002/eat.20327
7. Striegel-Moore RH, Rosselli F, Perrin N, DeBar L, Wilson GT, May A, et al. Gender difference in the prevalence of eating disorder symptoms. *Int J Eat Disord*. (2009) 42:471–4. doi: 10.1002/eat.20625

AUTHOR CONTRIBUTIONS

Study conceived by MS, RC-H, and DJN. Protocol written by MS, RC-H, DE, and DJN. Study documentation written by MS. Regulatory approvals obtained by MS, HD, DE, DJN, and RC-H. Supervision and guidance provided by RP, DEN, AL, TW, and TR. Statistical analysis plan by MS and AB. PPI facilitated by MS, HD, KA, and FM. Trial coordination by MS and HD. Data collection and analysis by MS, HD, RP, FM, KA, and JD. Trial clinical team FM, KA, JD, RP, and TR. All authors contributed to the article and approved the submitted version.

FUNDING

This study is funded by the funders of Imperial College London's Centre for Psychedelic Research (<https://www.imperial.ac.uk/psychedelic-research-centre/funding-partners/>), with specific support from The Nikean Foundation. Psilocybin has been supplied by COMPASS Pathways. HD was funded by the President's Ph.D. Scholarships.

ACKNOWLEDGMENTS

The authors would like to acknowledge the PPI attendees for giving their time to assist in the development of our trial. Further, we would also like to acknowledge Kenneth Jønck and Nicolai Lassen for creation of the online platform Psychedelic Survey, William Trender for assistance with the remote tasks, Matthew Wall, Natalie Ertl, Mari Lambrechts, and James Davies for development of the MRI tasks and sequences and Claire Power and Eva Casiechetty at Invicro LLC. We would like to thank Mendel Kaelen and Wavpaths for assistance developing the music playlist. Infrastructure support is to be provided by the NIHR Imperial Biomedical Research Centre and the NIHR Imperial Clinical Research Facility.

8. Arcelus J, Mitchell AJ, Wales J, Nielsen S. Mortality rates in patients with anorexia nervosa and other eating disorders: a meta-analysis of 36 studies. *Arch Gen Psychiatry*. (2011) 68:724–31. doi: 10.1001/archgenpsychiatry.2011.74
9. Keel PK, Dorner DJ, Eddy KT, Franko D, Charatan DL, Herzog DB. Predictors of mortality in eating disorders. *Arch Gen Psychiatry*. (2003) 60:179–83. doi: 10.1001/archpsyc.60.2.179
10. Abbate-Daga G, Amianto F, Delsedime N, De-Bacco C, Fassino S. Resistance to treatment and change in anorexia nervosa: a clinical overview. *BMC Psychiatry*. (2013) 13:294. doi: 10.1186/1471-244X-13-294
11. Button EJ, Marshall P, Shinkwin R, Black SH, Palmer RL. One hundred referrals to an eating disorders service: progress and service consumption over a 2–4 year period. *Euro Eat Disord Rev*. (1997) 5:47–63. doi: 10.1002/(SICI)1099-0968(199703)5:1<47::AID-ERV168>3.0.CO;2-R
12. Eivors A, Button E, Warner S, Turner K. Understanding the experience of drop-out from treatment for anorexia nervosa. *Euro Eat Disord Rev*. (2003) 11:90–107. doi: 10.1002/erv.492
13. Brockmeyer T, Friederich HC, Schmidt U. Advances in the treatment of anorexia nervosa: a review of established and emerging interventions. *Psychol Med*. (2018) 48:1228–56. doi: 10.1017/S0033291717002604
14. Fichter MM, Quadflieg N, Crosby RD, Koch S. Long-term outcome of anorexia nervosa: results from a large clinical longitudinal study. *Int J Eat Disord*. (2017) 50:1018–1030. doi: 10.1002/eat.22736

15. Eddy KT, Tabri N, Thomas JJ, Murray HB, Keshaviah A, Hastings E, et al. Recovery from anorexia nervosa and bulimia nervosa at 22-Year follow-up. *J Clin Psychiatry*. (2017) 78:184–89. doi: 10.4088/JCP.15m10393
16. Wonderlich SA, Bulik CM, Schmidt U, Steiger H, Hoek HW. Severe and enduring anorexia nervosa: update and observations about the current clinical reality. *Int J Eat Disord*. (2020) 53:1303–12. doi: 10.1002/eat.23283
17. Zhu J, Yang Y, Touyz S, Park R, Hay P. Psychological treatments for people with severe and enduring anorexia nervosa: a mini review. *Front Psychiatry*. (2020) 11:206. doi: 10.3389/fpsy.2020.00206
18. Woelbert E, Kirtley A, Balmer N, Dix S. How much is spent on mental health research: developing a system for categorising grant funding in the UK. *Lancet Psychiatry*. (2019) 6:445–52. doi: 10.1016/S2215-0366(19)30033-1
19. Woelbert E, Lundell-Smith K, White R, Kemmer D. Accounting for mental health research funding: developing a quantitative baseline of global investments. *Lancet Psychiatry*. (2021) 8:250–8. doi: 10.1016/S2215-0366(20)30469-7
20. Andersen KAA, Carhart-Harris R, Nutt DJ, Erritzoe D. Therapeutic effects of classic serotonergic psychedelics: a systematic review of modern-era clinical studies. *Acta Psychiatr Scand*. (2020) 143:101–18. doi: 10.1111/acps.13249
21. Bogenschutz MP, Forchimes AA, Pommy JA, Wilcox CE, Barbosa PCR, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. *J Psychopharmacol*. (2015) 29:289–99. doi: 10.1177/0269881114565144
22. Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Pilot study of the 5-HT_{2A}R agonist psilocybin in the treatment of tobacco addiction. *J Psychopharmacol*. (2014) 28:983–92. doi: 10.1177/0269881114548296
23. Johnson MW, Garcia-Romeu A, Griffiths RR. Long-term follow-up of psilocybin-facilitated smoking cessation. *Am J Drug Alcohol Abuse*. (2017) 43:55–60. doi: 10.3109/00952990.2016.1170135
24. Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. *J Clin Psychiatry*. (2006) 67:1735–40. doi: 10.4088/JCP.v67n1110
25. Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, et al. Trial of psilocybin versus escitalopram for depression. *N Engl J Med*. (2021) 384:1402–11. doi: 10.1056/NEJMoa2032994
26. Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. *Psychopharmacology*. (2018) 235:399–408. doi: 10.1007/s00213-017-4771-x
27. Carhart-Harris RL, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen M, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. *Lancet Psychiatry*. (2016) 3:619–27. doi: 10.1016/S2215-0366(16)30065-7
28. Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. *JAMA Psychiatry*. (2020) 78:481–9. doi: 10.1001/jamapsychiatry.2020.3285
29. Sanches RF, de Lima Osório F, Dos Santos RG, Macedo LR, Maia-de-Oliveira JP, Wichert-Ana L, et al. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a SPECT study. *J Clin Psychopharmacol*. (2016) 36:77–81. doi: 10.1097/JCP.0000000000000436
30. Gasser P, Kirchner K, Passie T. LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects. *J Psychopharmacol*. (2015) 29:57–68. doi: 10.1177/0269881114555249
31. Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. *J Psychopharmacol*. (2016) 30:1181–97. doi: 10.1177/0269881116675513
32. Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. *Arch Gen Psychiatry*. (2011) 68:71–8. doi: 10.1001/archgenpsychiatry.2010.116
33. Ross S, Bossis A, Guss J, Agin-Lieb G, Malone T, Cohen B, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. *J Psychopharmacol*. (2016) 30:1165–80. doi: 10.1177/0269881116675512
34. Brouwer A, Carhart-Harris RL. Pivotal mental states. *J Psychopharmacol*. (2020) 35:319–52. doi: 10.1177/0269881120959637
35. Carhart-Harris RL, Friston KJ. REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics. *Pharmacol Rev*. (2019) 71:316–44. doi: 10.1124/pr.118.017160
36. Carhart-Harris RL, Nutt DJ. Serotonin and brain function: a tale of two receptors. *J Psychopharmacol*. (2017) 31:1091–120. doi: 10.1177/0269881117725915
37. Herzog R, Mediano PAM, Rosas FE, Carhart-Harris R, Perl YS, Tagliazucchi E, et al. A mechanistic model of the neural entropy increase elicited by psychedelic drugs. *Sci Rep*. (2020) 10:17725. doi: 10.1038/s41598-020-74060-6
38. Griffiths RR, Johnson MW, Richards WA, Richards BD, McCann U, Jesse R. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. *Psychopharmacology*. (2011) 218:649–65. doi: 10.1007/s00213-011-2358-5
39. MacLean KA, Johnson MW, Griffiths RR. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. *J Psychopharmacol*. (2011) 25:1453–61. doi: 10.1177/0269881111420188
40. Roseman L, Nutt D, Carhart-Harris R. Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. *Front Pharmacol*. (2018) 8:974. doi: 10.3389/fphar.2017.00974
41. Roseman L, Haijen E, Idialu-Ikato K, Kaelen M, Watts R, Carhart-Harris R. Emotional breakthrough and psychedelics: validation of the emotional breakthrough inventory. *J Psychopharmacol*. (2019) 33:1076–87. doi: 10.1177/0269881119855974
42. Spriggs MJ, Kettner H, Carhart-Harris RL. Positive effects of psychedelics on depression and wellbeing scores in individuals reporting an eating disorder. *J Eat Weight Disord*. (2020) 26:1265–70. doi: 10.1007/s40519-020-01000-8
43. Kaye W. Neurobiology of anorexia and bulimia nervosa. *Physiol Behav*. (2008) 94:121–35. doi: 10.1016/j.physbeh.2007.11.037
44. Brandys MK, Kas MJH, Elburg AA, van, Campbell IC, Adan RAH. A meta-analysis of circulating BDNF concentrations in anorexia nervosa. *World J Biol Psychiatry*. (2011) 12:444–54. doi: 10.3109/15622975.2011.562244
45. Keegan E, Tchanturia K, Wade TD. Central coherence and set-shifting between nonunderweight eating disorders and anorexia nervosa: a systematic review and meta-analysis. *Int J Eat Disord*. (2021) 54:229–43. doi: 10.1002/eat.23430
46. Miles S, Gnat I, Phillipou A, Nedeljkovic M. Cognitive flexibility in acute anorexia nervosa and after recovery: a systematic review. *Clin Psychol Rev*. (2020) 81:101905. doi: 10.1016/j.cpr.2020.101905
47. Rawal A, Park RJ, Williams JMG. Rumination, experiential avoidance, and dysfunctional thinking in eating disorders. *Behav Res Ther*. (2010) 48:851–9. doi: 10.1016/j.brat.2010.05.009
48. Cowdrey FA, Park RJ. Assessing rumination in eating disorders: principal component analysis of a minimally modified ruminative response scale. *Eat Behav*. (2011) 12:321–4. doi: 10.1016/j.eatbeh.2011.08.001
49. Wildes JE, Ringham RM, Marcus MD. Emotion avoidance in patients with anorexia nervosa: initial test of a functional model. *Int J Eat Disord*. (2010) 43:398–404. doi: 10.1002/eat.20730
50. Murphy-Beiner A, Soar K. Ayahuasca's 'afterglow': improved mindfulness and cognitive flexibility in ayahuasca drinkers. *Psychopharmacology*. (2020) 237:1161–69. doi: 10.1007/s00213-019-05445-3
51. Zeifman RJ, Wagner AC, Watts R, Kettner H, Mertens LJ, Carhart-Harris RL. Post-Psychedelic reductions in experiential avoidance are associated with decreases in depression severity and suicidal ideation. *Front Psychiatry*. (2020) 11:782. doi: 10.3389/fpsy.2020.00782
52. Verroust V, Zafar R, Spriggs MJ. *Psilocybin in the Treatment of Anorexia Nervosa: The English Transition of a French 1959 Case Study La Psilocybine Dans le Traitement de Lanorexie Mentale: La Traduction en Anglais d'une Étude de Cas Française de 1959* (2021). doi: 10.1016/j.amp.2021.08.004
53. Lafrance A, Loizaga-Velder A, Fletcher J, Renelli M, Files N, Tupper KW. Nourishing the spirit: exploratory research on ayahuasca experiences along the continuum of recovery from eating disorders. *J Psychoactive Drugs*. (2017) 49:427–35. doi: 10.1080/02791072.2017.1361559

54. Renelli M, Fletcher J, Tupper KW, Files N, Loizaga-Velder A, Lafrance A. An exploratory study of experiences with conventional eating disorder treatment and ceremonial ayahuasca for the healing of eating disorders. *Eat Weight Disord.* (2018) 25:1–8. doi: 10.4324/9781315159645-17
55. Foldi CJ, Liknaitzky P, Williams M, Oldfield BJ. Rethinking therapeutic strategies for anorexia nervosa: insights from psychedelic medicine and animal models. *Front Neurosci.* (2020) 14:43. doi: 10.3389/fnins.2020.00043
56. Mockford C, Staniszewska S, Griffiths F, Herron-Marx S. The impact of patient and public involvement on UK NHS health care: a systematic review. *Int J Qual Health Care.* (2012) 24:28–38. doi: 10.1093/intqhc/mzr066
57. Thornton H. Patient and public involvement in clinical trials. *BMJ.* (2008) 336:903–4. doi: 10.1136/bmj.39547.586100.80
58. Involve NHS. *Public Involvement in Research: Values and Principles Framework.* (2015). Available online at: <https://www.invo.org.uk/wp-content/uploads/2017/08/Values-Principles-framework-Jan2016.pdf>
59. Close JB, Bornemann J, Piggin M, Jayacodi S, Luan LX, Carhart-Harris R, et al. Co-design of guidance for Patient and Public Involvement in Psychedelic Research. *Front Psychiatry.* (2021) 12:727496. doi: 10.3389/fpsy.2021.727496
60. Spriggs MJ, Douglass HM. *Involving Those With Lived Experience of Anorexia Nervosa in Clinical Trial Design.* (2021). Available online at: <http://www.imperial.ac.uk/blog/perc/2021/02/15/involving-those-with-lived-experience-of-anorexia-nervosa-in-clinical-trial-design/> (accessed May 19, 2021).
61. Staniszewska S, Brett J, Simera I, Seers K, Mockford C, Goodlad S, et al. GRIPP2 reporting checklists: tools to improve reporting of patient and public involvement in research. *BMJ.* (2017) 358:j3453. doi: 10.1136/bmj.j3453
62. Beresin E, Gordon C, Herzog D. The process of recovering from anorexia nervosa. *J Am Acad Psychoanal.* (1989) 17:103–30. doi: 10.1521/jaap.1.1989.17.1.103
63. D'Abundo M, Chally P. Struggling with recovery: participant perspectives on battling an eating disorder. *Qual Health Res.* (2004) 14:1094–106. doi: 10.1177/1049732304267753
64. Jenkins J, Ogden J. Becoming 'whole'again: a qualitative study of women's views of recovering from anorexia nervosa. *Euro Eat Disord Rev.* (2012) 20:e23–31. doi: 10.1002/erv.1085
65. Douglass L. Thinking through the body: the conceptualization of yoga as therapy for individuals with eating disorders. *Eat Disord.* (2011) 19:83–96. doi: 10.1080/10640266.2011.533607
66. Williams S, Reid M. Understanding the experience of ambivalence in anorexia nervosa: the maintainer's perspective. *Psychol Health.* (2010) 25:551–67. doi: 10.1080/08870440802617629
67. Friederich, H.-C., Brockmeyer T, Wild B, Resmark G, Zwaan M, et al. Emotional expression predicts treatment outcome in focal psychodynamic and cognitive behavioural therapy for anorexia nervosa: findings from the ANTOP study. *Psychother Psychosom.* (2017) 86:108–10. doi: 10.1159/000453582
68. Belser AB, Agin-Liebes G, Swift TC, Terrana S, Devenot N, Friedman HL, et al. Patient experiences of psilocybin-assisted psychotherapy: an interpretative phenomenological analysis. *J Hum Psychol.* (2017) 57:354–88. doi: 10.1177/0022167817706884
69. Gregertsen EC, Mandy W, Serpell L. The egosyntonic nature of anorexia: an impediment to recovery in anorexia nervosa treatment. *Front Psychol.* (2017) 8:2273. doi: 10.3389/fpsyg.2017.02273
70. Karlsson S, Friberg W, Rask M, Tuvevsson H. Patients' experiences and perceptions of recovering from anorexia nervosa while having contact with psychiatric care: a literature review and narrative synthesis of qualitative studies. *Issues Ment Health Nurs.* (2021) 42:709–719. doi: 10.1080/01612840.2020.1847222
71. Tan JOA, Hope T, Stewart A. Anorexia nervosa and personal identity: the accounts of patients and their parents. *Int J Law Psychiatry.* (2003) 26:533–48. doi: 10.1016/S0160-2527(03)00085-2
72. Tan J, Richards L. Legal and ethical issues in the treatment of really sick patients with anorexia nervosa. In: Robinson PH, Nicholls D, editors. *Critical Care for Anorexia Nervosa: The MARSIPAN Guidelines in Practice.* Cham: Springer International Publishing (2015). p. 113–50. doi: 10.1007/978-3-319-08174-8_6
73. Hope T, Tan J, Stewart A, McMillan J. Agency, ambivalence and authenticity: the many ways in which anorexia nervosa can affect autonomy1. *Int J Law Cont.* (2013) 9:20–36. doi: 10.1017/S1744552312000456
74. Nordbø RHS, Espeset EMS, Gulliksen KS, Skårderud F, Holte A. The meaning of self-starvation: qualitative study of patients' perception of anorexia nervosa. *Int J Eat Disord.* (2006) 39:556–64. doi: 10.1002/eat.20276
75. Serpell L, Teasdale JD, Troop NA, Treasure J. The development of the P-CAN, a measure to operationalize the pros and cons of anorexia nervosa. *Int J Eat Disord.* (2004) 36:416–33. doi: 10.1002/eat.20040
76. Skårderud F. Eating one's words, part I: 'Concretised metaphors' and reflective function in anorexia nervosa—an interview study. *Euro Eat Disord Rev.* (2007) 15:163–74. doi: 10.1002/erv.777
77. Cascino G, Castellini G, Stanghellini G, Ricca V, Cassioli E, Ruzzi V, et al. The role of the embodiment disturbance in the anorexia nervosa psychopathology: a network analysis study. *Brain Sci.* (2019) 9:276. doi: 10.3390/brainsci9100276
78. Stanghellini G, Castellini G, Brogna P, Faravelli C, Ricca V. Identity and eating disorders (IDEA): a questionnaire evaluating identity and embodiment in eating disorder patients. *Psychopathology.* (2012) 45:147–58. doi: 10.1159/000330258
79. Denison-Day J, Appleton KM, Newell C, Muir S. Improving motivation to change amongst individuals with eating disorders: a systematic review. *Int J Eat Disord.* (2018) 51:1033–50. doi: 10.1002/eat.22945
80. Schmidt U, Treasure J. Anorexia nervosa: valued and visible. A cognitive-interpersonal maintenance model and its implications for research and practice. *Br J Clin Psychol.* (2006) 45:343–66. doi: 10.1348/014466505X53902
81. Treasure J, Schmidt U. Ready, willing and able to change: motivational aspects of the assessment and treatment of eating disorders. *Euro Eat Disord Rev.* (2001) 9:4–18. doi: 10.1002/erv.390
82. Lancaster GA, Dodd S, Williamson PR. Design and analysis of pilot studies: recommendations for good practice. *J Eval Clin Pract.* (2004) 10:307–12. doi: 10.1111/j.2002.384.doc.x
83. Moore CG, Carter RE, Nietert PJ, Stewart PW. Recommendations for planning pilot studies in clinical and translational research. *Clin Transl Sci.* (2011) 4:332–7. doi: 10.1111/j.1752-8062.2011.00347.x
84. Thabane L, Ma J, Chu R, Cheng J, Ismaila A, Rios LP, et al. A tutorial on pilot studies: the what, why and how. *BMC Med Res Methodol.* (2010) 10:1. doi: 10.1186/1471-2288-10-1
85. Richardson C, Paslakis G. Men's experiences of eating disorder treatment: a qualitative systematic review of men-only studies. *J Psychiatr Ment Health Nurs.* (2021) 28:237–50. doi: 10.1111/jpm.12670
86. Robinson KJ, Mountford VA, Sperlinger DJ. Being men with eating disorders: perspectives of male eating disorder service-users. *J Health Psychol.* (2013) 18:176–86. doi: 10.1177/1359105312440298
87. Hudson JI, Hiripi E, Pope HG, Kessler RC. The prevalence and correlates of eating disorders in the national comorbidity survey replication. *Biol Psychiatry.* (2007) 61:348–58. doi: 10.1016/j.biopsych.2006.03.040
88. Frank GK, Shott ME. The role of psychotropic medications in the management of anorexia nervosa: rationale, evidence and future prospects. *CNS Drugs.* (2016) 30:419–42. doi: 10.1007/s40263-016-0335-6
89. Bonson KR, Buckholtz JW, Murphy DL. Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans. *Neuropsychopharmacology.* (1996) 14:425. doi: 10.1016/0893-133X(95)00145-4
90. Royal College of Psychiatrists. *Stopping Antidepressants.* Royal College of Psychiatrists. (2020). Available online at: <https://www.rcpsych.ac.uk/mental-health/treatments-and-wellbeing/stopping-antidepressants> (accessed June 1, 2021).
91. Park RJ, Singh I, Pike AC, Tan JO. Deep brain stimulation in anorexia nervosa: Hope for the hopeless or exploitation of the vulnerable? The oxford neuroethics gold standard framework. *Front Psychiatry.* (2017) 8:44. doi: 10.3389/fpsy.2017.00044
92. Appelbaum PS, Grisso T. *MacArthur Competence Assessment Tool for Clinical Research (MacCAT-CR).* Sarasota, FL: Professional Resource Press (2001).
93. Appelbaum PS, Grisso T, Frank E, O'Donnell S, Kupfer DJ. Competence of depressed patients for consent to research. *Am J Psychiatry.* (1999) 156:1380–4.

94. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *J Clin Psychiatry*. (1998) 59 (Suppl. 20):22–33;quiz 34–57.
95. Geller J, Brown KE, Srikameswaran S, Piper W, Dunn EC. The psychometric properties of the readiness and motivation questionnaire: a symptom-specific measure of readiness for change in the eating disorders. *Psychol Assess*. (2013) 25:759. doi: 10.1037/a0032539
96. Fairburn CG, Cooper Z, O'Connor M. The eating disorder examination. *Int J Eat Disord*. (1993) 6:1–8.
97. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med*. (2001) 16:606–13. doi: 10.1046/j.1525-1497.2001.016009606.x
98. Beck AT, Steer RA, Brown GK. Beck depression inventory-II. *San Antonio*. (1996) 78:490–8. doi: 10.1037/t00742-000
99. Tennant R, Hiller L, Fishwick R, Platt S, Joseph S, Weich S, et al. The warwick-edinburgh mental well-being scale (WEMWBS): development and UK validation. *Health Qual Life Outcomes*. (2007) 5:63. doi: 10.1186/1477-7525-5-63
100. Rolffs JL, Rogge RD, Wilson KG. Disentangling components of flexibility via the hexaflex model: development and validation of the multidimensional psychological flexibility inventory (MPFI). *Assessment*. (2018) 25:458–82. doi: 10.1177/1073191116645905
101. Gámez W, Chmielewski M, Kotov R, Ruggero C, Suzuki N, Watson D. The brief experiential avoidance questionnaire: development and initial validation. *Psychol Assess*. (2014) 26:35. doi: 10.1037/a0034473
102. Bellace DL, Tesser R, Berthod S, Wisotzke K, Crosby RD, Crow SJ, et al. The yale-brown-cornell eating disorders scale self-report questionnaire: a new, efficient tool for clinicians and researchers. *Int J Eat Disord*. (2012) 45:856–60. doi: 10.1002/eat.22023
103. Bohn K, Fairburn CG. Clinical Impairment Assessment Questionnaire (CIA 3.0). In: Fairburn CG, editors. *Cognitive Behavior Therapy and Eating Disorders*. New York, NY: Guilford Press (2008).
104. Spielberger CD, Gorsuch RC, Lushene RE. *Manual for the State-Trait Anxiety Inventory (Form Y): ("Self-Evaluation Questionnaire")*. Palo Alto, CA: Consulting Psychologists Press (1983).
105. Neff KD. The development and validation of a scale to measure self-compassion. *Self Ident*. (2003) 2:223–50. doi: 10.1080/15298860309027
106. Piran N, Teall TL, Counsell A. The experience of embodiment scale: development and psychometric evaluation. *Body Image*. (2020) 34:117–34. doi: 10.1016/j.bodyim.2020.05.007
107. Martin M, Rubin R. A new measure of cognitive flexibility. *Psychol Rep*. (1995) 76:623–6. doi: 10.2466/pr0.1995.76.2.623
108. Brown TA, Berner LA, Jones MD, Reilly EE, Cusack A, Anderson LK, et al. Psychometric evaluation and norms for the multidimensional assessment of interoceptive awareness (MAIA) in a clinical eating disorders sample. *Euro Eat Disord Rev*. (2017) 25:411–6. doi: 10.1002/erv.2532
109. Gilbert P, Clarke M, Hempel S, Miles JN, Irons C. Criticizing and reassuring oneself: an exploration of forms, styles and reasons in female students. *Br J Clin Psychol*. (2004) 43:31–50. doi: 10.1348/014466504772812959
110. Gilbert P, Catarino F, Duarte C, Matos M, Kolts R, Stubbs J, et al. The development of compassionate engagement and action scales for self and others. *J Compass Health Care*. (2017) 4:4. doi: 10.1186/s40639-017-0033-3
111. Brown M, Robinson L, Campione GC, Wuensch K, Hildebrandt T, Micali N. Intolerance of uncertainty in eating disorders: a systematic review and meta-analysis. *Euro Eat Disord Rev*. (2017) 25:329–43. doi: 10.1002/erv.2523
112. Studerus E, Gamma A, Vollenweider FX. Psychometric evaluation of the altered states of consciousness rating scale (OAV). *PLoS ONE*. (2010) 5:e12412. doi: 10.1371/journal.pone.0012412
113. Barrett FS, Bradstreet MP, Leoutsakos JMS, Johnson MW, Griffiths RR. The challenging experience questionnaire: characterization of challenging experiences with psilocybin mushrooms. *J Psychopharmacol*. (2016) 30:1279–95. doi: 10.1177/0269881116678781
114. Tanay G, Bernstein A. State mindfulness scale (SMS): development and initial validation. *Psychol Assess*. (2013) 25:1286–99. doi: 10.1037/a0034044
115. Berntsen D, Rubin DC. The centrality of event scale: a measure of integrating a trauma into one's identity and its relation to post-traumatic stress disorder symptoms. *Behav Res Ther*. (2006) 44:219–31. doi: 10.1016/j.brat.2005.01.009
116. Felitti VJ, Anda RF, Nordenberg D, Williamson DF, Spitz AM, Edwards V, et al. Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults: the adverse childhood experiences (ACE) study. *Am J Prev Med*. (1998) 14:245–58. doi: 10.1016/S0749-3797(98)00017-8
117. Kotov RI, Bellman SB, Watson DB. *Multidimensional Iowa Suggestibility Scale (MISS)*. Stony Brook University (2004). Retrieved from https://ir.stonybrook.edu/xmlui/bitstream/handle/11401/66341/MISS_FINAL_BLANK_0.pdf?sequence=1
118. Tellegen A, Atkinson G. Openness to absorbing and self-altering experiences ('absorption'), a trait related to hypnotic susceptibility. *J Abnorm Psychol*. (1974) 83:268. doi: 10.1037/h0036681
119. McGuire-Snieckus R, McCabe R, Catty J, Hansson L, Priebe S. A new scale to assess the therapeutic relationship in community mental health care: STAR. *Psychol Med*. (2007) 37:85–95. doi: 10.1017/S0033291706009299
120. Reitan RM. Validity of the trail making test as an indicator of organic brain damage. *Percept Mot Skills*. (1958) 8:271–6. doi: 10.2466/pms.1958.8.3.271
121. Grant DA, Berg E. A behavioral analysis of degree of reinforcement and ease of shifting to new responses in a weigl-type card-sorting problem. *J Exp Psychol*. (1948) 38:404–11. doi: 10.1037/h0059831
122. Cowdrey FA, Finlayson G, Park RJ. Liking compared with wanting for high-and low-calorie foods in anorexia nervosa: aberrant food reward even after weight restoration-. *Am J Clin Nutr*. (2013) 97:463–70. doi: 10.3945/ajcn.112.046011
123. Legrand N, Nikolova N, Correa C, Brændholt M, Stuckert A, Kildahl N, et al. The heart rate discrimination task: a psychophysical method to estimate the accuracy and precision of interoceptive beliefs. *BioRxiv*. (2021) 2021.02.18.431871. doi: 10.1101/2021.02.18.431871
124. Wolff M, Evens R, Mertens LJ, Koslowski M, Betzler F, Gründer G, et al. Learning to let go: a cognitive-behavioral model of how psychedelic therapy promotes acceptance. *Front Psychiatry*. (2020) 11:5. doi: 10.3389/fpsy.2020.00005
125. Luoma JB, Sabucedo P, Eriksson J, Gates N, Pilecki BC. Toward a contextual psychedelic-assisted therapy: perspectives from acceptance and commitment model and contextual behavioral science. *J Context Behav Sci*. (2019) 14:136–45. doi: 10.1016/j.jcbs.2019.10.003
126. Sloschower J, Guss J, Krause R, Wallace RM, Williams MT, Reed S, et al. Psilocybin-assisted therapy of major depressive disorder using acceptance and commitment therapy as a therapeutic frame. *J Context Behav Sci*. (2020) 15:12–9. doi: 10.1016/j.jcbs.2019.11.002
127. Watts R, Luoma JB. The use of the psychological flexibility model to support psychedelic assisted therapy. *J Context Behav Sci*. (2020) 15:92–102. doi: 10.1016/j.jcbs.2019.12.004
128. Bogenschutz MP, Forcehimes AA. Development of a psychotherapeutic model for psilocybin-assisted treatment of alcoholism. *J Hum Psychol*. (2017) 57:389–414. doi: 10.1177/0022167816673493
129. Lafrance A, Robison R. *Psychedelics and Eating Disorders*. (2021). Available online at: <https://www.edcatalogue.com/psychedelics-eating-disorders/> (accessed June 30, 2021).
130. National Institute for Health and Care Excellence. *Eating Disorders: Recognition and Treatment*. National Institute for Health and Care Excellence (2017). Available online at: <https://www.nice.org.uk/guidance/ng69>
131. Byrne CE, Accurso EC, Arnow KD, Lock J, Le Grange D. An exploratory examination of patient and parental self-efficacy as predictors of weight gain in adolescents with anorexia nervosa. *Int J Eat Disord*. (2015) 48:883–8. doi: 10.1002/eat.22376
132. Goddard E, Macdonald P, Sepulveda AR, Naumann U, Landau S, Schmidt U, et al. Cognitive interpersonal maintenance model of eating disorders: Intervention for carers. *Br J Psychiatry*. (2011) 199:225–31. doi: 10.1192/bjp.bp.110.088401
133. Robinson AL, Dolhanty J, Stillar A, Henderson K, Mayman S. Emotion-focused family therapy for eating disorders across the lifespan: a pilot study of a 2-day transdiagnostic intervention for parents. *Clin Psychol Psychother*. (2016) 23:14–23. doi: 10.1002/cpp.1933

134. Robinson AL, Strahan E, Girz L, Wilson A, Boachie A. 'I know i can help you': parental self-efficacy predicts adolescent outcomes in family-based therapy for eating disorders. *Euro Eat Disord Rev.* (2013) 21:108–14. doi: 10.1002/erv.2180
135. Geller J, Cockell SJ, Drab DL. Assessing readiness for change in the eating disorders: the psychometric properties of the readiness and motivation interview. *Psychol Assess.* (2001) 13:189. doi: 10.1037/1040-3590.13.2.189
136. Geller J, Maiolino N, Samson L, Srikaneswaran S. Is experiencing care as collaborative associated with enhanced outcomes in inpatient eating disorders treatment? *Eat Disord.* (2019) 29:539–49. doi: 10.1080/10640266.2019.1695452
137. Geller J, Drab DL. The readiness and motivation interview: a symptom-specific measure of readiness for change in the eating disorders. *Euro Eat Disord Rev.* (1999) 7:259–78. doi: 10.1002/(SICI)1099-0968(199908)7:4<259::AID-ERV295>3.0.CO;2-6
138. Shingleton RM, Pratt EM, Gorman B, Barlow DH, Palfai TP, Thompson-Brenner H. Motivational text message intervention for eating disorders: a single-case alternating treatment design using ecological momentary assessment. *Behav Ther.* (2016) 47:325–38. doi: 10.1016/j.beth.2016.01.005
139. Allen KL, Fursland A, Raykos B, Steele A, Watson H, Byrne SM. Motivation-focused treatment for eating disorders: a sequential trial of enhanced cognitive behaviour therapy with and without preceding motivation-focused therapy. *Euro Eat Disord Rev.* (2012) 20:232–9. doi: 10.1002/erv.1131
140. Geller J, Cassin SE, Brown KE, Srikaneswaran S. Factors associated with improvements in readiness for change: low vs. normal BMI eating disorders. *Int J Eat Disord.* (2009) 42:40–6. doi: 10.1002/eat.20574
141. O'Brien KM, Vincent NK. Psychiatric comorbidity in anorexia and bulimia nervosa: Nature, prevalence, causal relationships. *Clin Psychol Rev.* (2003) 23:57–74. doi: 10.1016/S0272-7358(02)00201-5
142. Seidler D, Stone B, Clark BE, Koran J, Drake CE. Evaluating the factor structure of the multidimensional psychological flexibility inventory: an independent replication and extension. *J Context Behav Sci.* (2020) 17:23–31. doi: 10.1016/j.jcbs.2020.04.007
143. Haijen EC, Kaelen M, Roseman L, Timmermann C, Kettner H, Russ S, et al. Predicting responses to psychedelics: a prospective study. *Front Pharmacol.* (2018) 9:897. doi: 10.3389/fphar.2018.00897
144. Sumner RL, McMillan R, Spriggs MJ, Campbell D, Malpas G, Maxwell E, et al. Ketamine improves short-term plasticity in depression by enhancing sensitivity to prediction errors. *Euro Neuropsychopharmacol.* (2020) 38:73–85. doi: 10.1016/j.euroneuro.2020.07.009
145. Spriggs M, Sumner R, McMillan R, Moran R, Kirk I, Muthukumaraswamy S. Indexing sensory plasticity: evidence for distinct predictive coding and hebbian learning mechanisms in the cerebral cortex. *Neuroimage.* (2018) 176:290–300. doi: 10.1016/j.neuroimage.2018.04.060
146. Sumner RL, Spriggs MJ, Muthukumaraswamy SD, Kirk IJ. The role of Hebbian learning in human perception: a methodological and theoretical review of the human visual long-term potentiation paradigm. *Neurosci Biobehav Rev.* (2020) 115:220–37. doi: 10.1016/j.neubiorev.2020.03.013

Author Disclaimer: The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

Conflict of Interest: RC-H reports receiving consulting fees from COMPASS Pathways, Entheon Biomedical, Mydecine, Synthesis Institute, Tryp Therapeutics, and Usona Institute; DE receiving consulting fees from Field Trip and Mydecine and Entheon Biomedical; and DJN receiving consulting fees from Awakn, H. Lundbeck, and Psyched Wellness, advisory board fees from COMPASS Pathways, and lecture fees from Takeda Medical Research Foundation and owning stock in Alcarelle.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Spriggs, Douglass, Park, Read, Danby, de Magalhães, Alderton, Williams, Blemings, Lafrance, Nicholls, Erritzoe, Nutt and Carhart-Harris. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.